Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ATI-1777 2.0% w/w · 1 trial · 1 indication
EASI is a validated composite scoring system integrating the proportion of the body region (area) involved and the intensity of key signs of atopic dermatitis (AD). The EASI score examines 4 areas of the body and weights them for participants 8 years of age and older as follows: Head/Neck (H) = 0.1, Upper limbs (UL) = 0.2, Trunk (T) = 0.3, and Lower limbs (LL) = 0.4. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The total EASI score ranges from 0 to 72. A higher score indicated worse disease status, and a negative change from baseline indicated improvement.
| Arm | Type | Description |
|---|---|---|
| ATI-1777 topical solution 2.0% w/w (BID) | EXPERIMENTAL | ATI-1777 topical solution 2.0% w/w, twice daily |
| ATI-1777 topical solution 1.0% w/w (BID) | EXPERIMENTAL | ATI-1777 topical solution 1.0% w/w, twice daily |
| ATI-1777 topical solution 0.5% w/w (BID) | EXPERIMENTAL | ATI-1777 topical solution 0.5% w/w, twice daily |
| Vehicle (BID) | PLACEBO_COMPARATOR | Vehicle topical solution, twice daily |
| ATI-1777 topical solution 2.0% w/w (QD) | EXPERIMENTAL | ATI-1777 topical solution 2.0% w/w, once daily |
| Vehicle (QD) | PLACEBO_COMPARATOR | Vehicle topical solution, once daily |
| Name | Type | Description |
|---|---|---|
| ATI-1777 2.0% w/w | DRUG | ATI-1777 topical solution 2.0% w/w |
| ATI-1777 1.0% w/w | DRUG | ATI-1777 topical solution 1.0% w/w |
| ATI-1777 0.5% w/w | DRUG | ATI-1777 topical solution 0.5% w/w |
| Vehicle | DRUG | Vehicle topical solution |
Inclusion Criteria: 1. Able to comprehend and willing to sign the IRB approved ICF/assent prior to administration of study-related procedures. 2. Male patients or non-pregnant, non-nursing female patients 12 to 65 years old, inclusive, at the time of informed consent/assent. 3. Have at least a 6-mo...
Top 20 of 25 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 9 | PHASE3 | Upadacitinib, corticosteroids |
| Pfizer Inc. | PFE | 11 | PHASE3 | Abrocitinib |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Lebrikizumab, Corticosteroid |
| Sanofi SA Sponsored ADR | SNY | 13 | PHASE3 | Amlitelimab |
| Regeneron Pharmaceuticals, Inc. | REGN | 4 | PHASE3 | Dupilumab |
| Incyte Corporation | INCY | 3 | PHASE3 | Ruxolitinib, Vehicle |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof, 1%, Vehicle |
| Apogee Therapeutics, Inc. | APGE | 3 | PHASE2 | APG777 |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | GIA632 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Corvus Pharmaceuticals, Inc. | CRVS | 1 | PHASE2 | Soquelitinib |
| Nektar Therapeutics | NKTR | 1 | PHASE2 | Rezpegaldesleukin |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE2 | Barzolvolimab |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
| Sunshine Biopharma Incorporated | SBFM | 3 | PHASE3 | 611, corticosteroid |
| Aclaris Therapeutics, Inc. | ACRS | 1 | PHASE2 | ATI-045 |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | ADX-914 |
| Turn Therapeutics Inc. | TTRX | 1 | PHASE2 | GX-03 |
| Arcutis Biotherapeutics Inc | ARQT | 1 | PHASE1 | ARQ-234 |
ATI-1777 is an investigational small molecule being developed for the treatment of atopic dermatitis, a chronic inflammatory skin condition. It is formulated as a 2.0% w/w topical product. The drug is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
ATI-1777 is being developed by Aclaris Therapeutics, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol ACRS. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational topical treatment for atopic dermatitis.
ATI-1777 is in Phase 2 clinical development. A Phase 2 study has been completed, evaluating the drug in patients aged 12 to 65 years with mild to severe atopic dermatitis. The drug is investigational and has not received FDA approval.
ATI-1777 has one completed Phase 2 clinical trial, identified as NCT05432596. This randomized, double-blind, placebo-controlled study enrolled 250 participants with mild to severe atopic dermatitis in the United States. The trial included patients aged 12 years and older.
ATI-1777 is a small molecule designed to treat atopic dermatitis, but its specific molecular target has not been disclosed. The drug is applied topically as a 2.0% w/w formulation, intended to address the inflammatory processes underlying the skin condition.